Adaptimmune Therapeutics (NASDAQ:ADAP) Shares Pass Above Fifty Day Moving Average of $1.81
Adaptimmune Therapeutics (NASDAQ:ADAP) Shares Pass Above Fifty Day Moving Average of $1.81
Adaptimmune Therapeutics plc (NASDAQ:ADAP – Get Rating)'s share price crossed above its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $1.81 and traded as high as $2.54. Adaptimmune Therapeutics shares last traded at $2.38, with a volume of 567,183 shares.
在週五的交易中，Adaptimmune Treateutics公司(納斯達克代碼：ADAP-GET Rating)的股價突破了50日移動均線。該股的50日移動均線切入位為1.81美元，最高交易價格為2.54美元。Adaptimmune Treateutics的股票最新報2.38美元，成交量為567,183股。
Adaptimmune Therapeutics Price Performance
Adaptimmune治療藥物價格表現
The firm has a market cap of $385.61 million, a PE ratio of -2.12 and a beta of 1.79. The stock's fifty day moving average price is $1.81 and its 200-day moving average price is $2.01.
該公司市值為3.8561億美元，市盈率為-2.12，貝塔係數為1.79。該股的50日移動均線價格為1.81美元，200日移動均線價格為2.01美元。
Institutional Investors Weigh In On Adaptimmune Therapeutics
機構投資者看好Adaptimmune Treeutics
A number of hedge funds have recently modified their holdings of the company. Alps Advisors Inc. purchased a new stake in shares of Adaptimmune Therapeutics in the second quarter valued at about $163,000. JPMorgan Chase & Co. grew its holdings in shares of Adaptimmune Therapeutics by 5.3% in the second quarter. JPMorgan Chase & Co. now owns 1,474,163 shares of the biotechnology company's stock valued at $2,506,000 after purchasing an additional 74,398 shares during the period. Hunter Associates Investment Management LLC grew its holdings in shares of Adaptimmune Therapeutics by 42.5% in the second quarter. Hunter Associates Investment Management LLC now owns 28,500 shares of the biotechnology company's stock valued at $49,000 after purchasing an additional 8,500 shares during the period. Vigilare Wealth Management purchased a new stake in shares of Adaptimmune Therapeutics in the second quarter valued at about $71,000. Finally, Virtu Financial LLC purchased a new stake in shares of Adaptimmune Therapeutics in the first quarter valued at about $50,000.
多家對衝基金最近調整了對該公司的持股。Alps Advisors Inc.在第二季度購買了Adaptimmune Treateutics的新股，價值約16.3萬美元。摩根大通第二季度增持Adaptimmune Treeutics股票5.3%。摩根大通公司目前持有這家生物技術公司1,474,163股股票，價值2,506,000美元，在此期間又購買了74,398股。Hunter Associates Investment Management LLC在第二季度持有的Adaptimmune Treeutics股票增加了42.5%。Hunter Associates Investment Management LLC在此期間又購買了8500股，現在擁有28500股這家生物技術公司的股票，價值4.9萬美元。Vigilare Wealth Management在第二季度購買了Adaptimmune Treeutics的新股份，價值約71,000美元。最後，Virtu Financial LLC在第一季度購買了Adaptimmune Treeutics的新股份，價值約5萬美元。
About Adaptimmune Therapeutics
關於適應性免疫療法
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets.
Adaptimmune Treateutics公司是一家臨牀階段的生物製藥公司，主要為美國和英國的實體腫瘤患者提供新型細胞療法。該公司的特定多肽增強親和力受體(SPEAR)T細胞平臺使其能夠識別癌症靶點。
Read More
閲讀更多內容
- Get a free copy of the StockNews.com research report on Adaptimmune Therapeutics (ADAP)
- 2 Important Retail Stock Battles to Watch
- MarketBeat: Week in Review 8/8 – 8/12
- What Is WallStreetBets and What Stocks Are They Targeting?
- Institutions And Analysts Propel Jack In The Box Higher
- Can You Guess Which EV Stock Is Beating Tesla ?
- 免費獲取StockNews.com關於Adaptimmune治療(ADAP)的研究報告
- 值得關注的兩場重要的零售股大戰
- MarketBeat：回顧中的一週2012-8-8
- 什麼是WallStreetBets，他們的目標是什麼股票？
- 機構和分析師推動Jack in the Box走高
- 你能猜到哪個電動車股票打敗了特斯拉嗎？
Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《適應性免疫治療日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Adaptimmune Treeutics和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。